News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
December, 2024
December 2024
M T W T F S S
 1
2345678
9101112131415
16171819202122
23242526272829
3031  
Andres Gomez: Venetoclax can be effectively reduced to 100 mg when combined with azoles in a first-line, phase 2 trial done under limited resources.
Photo from Andres Gomez/Twitter
Aug 29, 2023, 19:15

Andres Gomez: Venetoclax can be effectively reduced to 100 mg when combined with azoles in a first-line, phase 2 trial done under limited resources.

Andres Gomez, an Associate Professor at Universidad Autónoma de Nuevo León, Mexico, recently tweeted:

“Venetoclax is an expensive life-saving drug in AML. We have proven it can be effectively reduced to 100 mg when combined with azoles in a first-line, phase 2 trial done under limited resources.

Out now in Leuk Res, access here:”

Source: Andres Gomez/Twitter

Andres Gomez cancer OncoDaily Oncology Twitter venetoclax
Special Coverage
Science
Dec 28, 2024, 17:52
From supportive care to trauma - The Multinational Association of Supportive Care in Cancer
Science
Dec 28, 2024, 17:48
Niharika Dixit: Group medical visits could be a key component of multidisciplinary care for cancer survivors
Blog
Dec 28, 2024, 17:37
2024 Pancreas Wrapped by Giovanni Marchegiani
Science
Dec 28, 2024, 17:33
Saurabh Zanwar: Is risk-adapted therapy ready for prime time in Multiple Myeloma?
Blog
Dec 28, 2024, 16:31
Patela Care Foundation: Celebrating this season and forging treasured memories with the triumphant pediatric champions
Blog
Dec 28, 2024, 16:28
Brett Wilson: Be the LIGHT OF HOPE for Walking Miracles This Year in West Virginia and Pittsburgh
Blog
Dec 28, 2024, 16:23
Sarah Cannon Transplant and Cellular Therapy Network is hiring
Career
Dec 28, 2024, 16:17
Brian Vesall Received the Jordan Jones Memorial Achievement Award for Advocacy and Leadership
Science
Dec 28, 2024, 16:08
Jonathan Govette: AI in Healthcare: Bridging the Gap Between Potential and Adoption
Career
Dec 28, 2024, 16:06
Join the CCI Europe team as a Junior Projects Coordinator in Vienna
Science
Dec 28, 2024, 15:55
Chris Boerner: The FDA approved our new subcutaneous immunotherapy treatment
Science
Dec 28, 2024, 15:46
Vivek Subbiah: Our paper on the development of PROTAC degraders of oncogenic RET protein